This study was an evaluation, at 12 months follow-up, of anti VEGF treatment for diabetic macular edema conducted in a real world setting. To examine objective visual acuity measured with ETDRS, retinal thickness (OCT), patient reported outcome and describe levels of glycated hemoglobin and its association with the effects on visual acuity in patients treated with anti-VEGF for visual impairment …
anti-VEGF
Topical Dorzolamide-Timolol With Intravitreous Anti–Vascular Endothelial Growth Factor for Neovascular Age-Related Macular Degeneration
Topical dorzolamide hydrochloride-timolol appears to reduce central subfield thickness and subretinal fluid in eyes of patients with neovascular age-related macular degeneration (AMD) and incomplete response to anti-vascular endothelial growth factor (VEGF) therapy, according to a study published online Feb. 25 in JAMA Ophthalmology. Jayanth Sridhar, M.D., from the Thomas Jefferson University in …
New Trial Shows Drugs are Effective for Diabetic Macular Edema
Diabetes is a significant risk factor for developing eye diseases. The most common diabetic eye disease and a leading cause of blindness is diabetic retinopathy. Americans with diabetic retinopathy have diabetic macular edema (DME) in which fluid leaks into the macula, the area of the retina used when looking straight ahead. Over the past few years, drugs that target VEGF have become a standard …